Head-to-head · WeighScore
Zealthy vs Zera Health
The verdict
Zera Health takes it — 74.8/100 to 46.7/100.
Zera Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Zera Health is a telehealth platform for compounded GLP-1 weight loss — semaglutide from $149/mo, tirzepatide from $199/mo, plus oral and low-dose microdose options — prescribed by licensed physicians in…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Zealthy | Zera Health |
|---|---|---|
| WeighScore | 46.7/100 | 74.8/100 |
| Grade | C | C |
| Scorecard rank | #496 | #61 |
| Semaglutide | $286/mo (starting dose, plus a separate fee, compounded) | $149/mo (compounded) |
| Tirzepatide | $351/mo (starting dose, plus a separate fee, compounded) | $199/mo (compounded) |
| Coverage | 34 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Graded #61 · C
Strengths
- Compounded semaglutide from $149/mo and tirzepatide from $199/mo, plus a $129/mo microdose option
- Flat pricing — the same monthly cost at every dose as you titrate up
- All-inclusive: medication, unlimited 24/7 provider messaging, and free shipping bundled in
- Names its compounding pharmacy — Strive Pharmacy (licensed 503A)
- Available in all 50 states with same-day approvals
Where it loses points
- Operates as a technology platform, not the medical provider itself
- Compounded GLP-1s are not FDA-approved (the site discloses this honestly)
- Aggressive marketing results claims (e.g. '18% average', '93% kept it off') with 'results not typical' disclaimers
- Legal entity name not published (footer shows only 'Zera Health')
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.